A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Bertrand Arnulf(Université Paris Cité), Lionel Karlin(Hôpital Lyon Sud), Pierre Morel(Institut für Gießereitechnik), Sylvie Chevret(Saint Louis University Hospital), Cyrille Touzeau(Centre National de la Recherche Scientifique), David Lavergne, Margaret Macro(Hôpital Cochin), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Fabien Le Bras, Giovanni Palladini(University of Pavia), Aurore Perrot(Institut universitaire du cancer de Toulouse Oncopole), Giampaolo Merlini(University of Pavia), Frank Bridoux(Université de Poitiers), Laurent Frenzel(Hôpital Necker-Enfants Malades), Anne Marie Stoppa, Véronique Dorvaux, Antoine Huart, Eileen M. Boyle(BMW (Germany))
Cited by 128
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k